Previous 10 | Next 10 |
Theravance Biopharma, Inc. (TBPH) Q2 2020 Earnings Conference Call August 6, 2020 5:00 PM ET Company Participants Gail Cohen – Vice President, Corporate Communications and Investor Relations Rick Winningham – Chief Executive Officer Frank Pasqualone – Chief C...
The following slide deck was published by Theravance Biopharma, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Image source: The Motley Fool. Theravance Biopharma Inc (NASDAQ: TBPH) Q2 2020 Earnings Call Aug 6, 2020 , 5:00 p.m. ET Operator Continue reading
Theravance Biopharma (NASDAQ: TBPH ) : Q2 GAAP EPS of -$1.00 beats by $0.04 . More news on: Theravance Biopharma, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
DUBLIN , Aug. 6, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ: TBPH) today reported financial results for the second quarter ending June 30, 2020 . Revenue for the second quarter 2020 was $15.0 million . Operating loss was $72.2 mill...
DUBLIN , July 27, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, will report its second quarter 2020 financial results and prov...
Last year I created a public screen on Portfolio123, a web-based subscription service that allows you to backtest screens and ranking systems. It invests in companies in the Russell 3000 that spend heavily on R&D. There were four rules in the screen, but the most important were these: ...
DUBLIN , July 2, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced the appoin...
The first UK patient has been dosed in a 159-subject Phase 2 clinical trial evaluating Theravance Biopharma's (NASDAQ: TBPH ) Janus kinase inhibitor TD-0903 in hospitalized COVID-19 patients with acute lung injury (ALI). More news on: Theravance Biopharma, Inc., Healthcare stocks news,...
DUBLIN and SOUTH SAN FRANCISCO, Calif. , June 25, 2020 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company"), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective me...
News, Short Squeeze, Breakout and More Instantly...
Theravance Biopharma Inc. Company Name:
TBPH Stock Symbol:
NASDAQ Market:
Theravance Biopharma Inc. Website:
2024-06-15 00:02:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Theravance Biopharma, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update PR Newswire Q1 2024 YUPELRI ® (revefenacin) net sales of $55.2 million , recognized by Viatris, increased 18% from Q1 2023 1 Viatris collaboratio...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...